Clinical trials: HIV/AIDS
HIV-1
A Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Antiviral Activity of Rilpivirine (TMC278) in Human Immunodeficiency Virus Infected Adolescents and Children Aged Greater Than or Equal to 6 Years
The purpose of this study is to evaluate the pharmacokinetics, safety and antiviral activity of rilpivirine (TMC278) 25 milligram (mg) or adjusted dose once daily in combination with an investigator-selected background regimen…
- Trial name
- NCT00799864
- Testing
- Rilpivirine, Zidovudine, Abacavir
- Where
- 17 sites in United States, India and 6 more
- Volunteers
- 54 people
- Sponsor
- Janssen Sciences Ireland UC
HIV-associated Tuberculosis
Pharmacokinetics and Safety of Double-dose Dolutegravir When Used With Rifapentine for HIV-associated Tuberculosis
A5406 hypothesized that dolutegravir (DTG) 50 mg taken twice daily provides adequate exposures to maintain viral suppression when dosed with rifapentine (RPT) 1200 mg for HIV-associated tuberculosis (TB).
- Trial name
- NCT05630872
- Testing
- Dolutegravir (DTG) 50 mg orally BID (~12 hours apart) plus TDF/3TC, DTG 50 mg orally QD plus TDF/3TC, 2HPZM
- Where
- 4 sites in South Africa, Thailand
- Volunteers
- 30 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Alcohol; Harmful Use, Binge Drinking
Computerized Brief Alcohol Intervention (BI) for Binge Drinking HIV At-Risk and Infected Women
African American (AA) women are disproportionately affected by HIV/AIDs. The major risk factor for HIV acquisition among AA women is high-risk heterosexual sex, including unprotected vaginal and anal sex, and sex with a high-risk…
- Conditions
- Alcohol; Harmful Use, Binge Drinking, Risk Behavior, HIV Infection
- Trial name
- NCT01125371
- Testing
- Computerized brief alcohol intervention + IVR booster calls, Computerized brief alcohol intervention, Attention Control
- Where
- United States
- Volunteers
- 439 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
HIV Infections
The Safety and Immunogenicity of a Potential HIV Vaccine
The potential HIV vaccine has two components: a protein immunogen based on the coat protein of HIV; and an adjuvant which enhances the vaccinee's response to the immunogen.
- Trial name
- NCT01966900
- Testing
- CN54gp140 mixed with GLA-AF
- Where
- United Kingdom
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Substance-related Disorders
Working With HIV Clinics to Adopt Addiction Treatments Using Implementation Facilitation
Tobacco, alcohol and opioid use disorders threaten the health of HIV-infected patients. What if evidence-based counseling and medication treatments for tobacco, alcohol and opioid use disorders (herein refered to as addiction…
- Trial name
- WHAT-IF? (NCT02907944)
- Testing
- Implementation Facilitation
- Where
- 4 sites in United States
- Volunteers
- 3,838 people
- Sponsor
- Yale University
Lymphoma
Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed, HIV-Associated Burkitt's Lymphoma
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.
- Trial name
- NCT00392834
- Testing
- filgrastim, pegfilgrastim, rituximab
- Where
- 13 sites in United States
- Volunteers
- 34 people
- Sponsor
- AIDS Malignancy Consortium
HIV, Sexually Transmitted Diseases
LYNX: A Novel Mobile App to Support Linkage to HIV/STI Testing PrEP for Young Men Who Have Sex With Men
This study is testing the acceptability and feasibility of a highly interactive mobile application (app) to promote HIV/sexually transmitted infection (STI) testing and uptake of pre-exposure prophylaxis (PrEP) among young men…
- Conditions
- HIV, Sexually Transmitted Diseases, Risk Reduction, Pre-Exposure Prophylaxis
- Trial name
- NCT03177512
- Testing
- LYNX Mobile App
- Where
- 2 sites in United States
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Public Health Foundation Enterprises, Inc.
HIV Infections
China Antiretroviral Treatment Adherence for Life
This study focuses on collecting and analyzing quantitative data related to adherence to antiretroviral treatment from patients in Dali, China, over a one-year time-frame and generating preliminary data on an intervention…
- Trial name
- AFL (NCT00661258)
- Testing
- Electronic drug monitoring feedback data
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Boston University
HIV Infections
Optimizing Pediatric HIV-1 Treatment, Nairobi, Kenya
Given the high mortality associated with infant HIV-1 and the fact that surrogate markers are poorly predictive of mortality risk,empiric highly active antiretroviral therapy (HAART) initiation is started in infants younger than…
- Trial name
- NCT00428116
- Testing
- HAART
- Volunteers
- 140 people
- Sponsor
- University of Washington
HIV
Combination Therapy With 3BNC117 and 10-1074 in HIV-Infected Individuals
Background: Human immunodeficiency virus (HIV) affects the immune system. The main function of the immune system is protect you from infections and other diseases such as cancer.
- Trial name
- NCT03571204
- Testing
- 3BNC117 and 10-1074
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
The purpose of this study was to examine the pharmacokinetics, safety, and tolerability of abacavir/dolutegravir/lamivudine dispersible and immediate release tablets in children living with HIV less than 12 years of age.
- Trial name
- NCT03760458
- Testing
- Abacavir (ABC)/Dolutegravir (DTG)/Lamivudine (3TC) Dispersible Tablets, Abacavir (ABC)/Dolutegravir (DTG)/Lamivudine (3TC) Immediate Release Tablets (Immediate release)
- Where
- 14 sites in United States, Botswana and 2 more
- Volunteers
- 57 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV
Safety and Pharmacokinetics (PK) of a Polyurethane Tenofovir Disoproxil Fumarate (TDF) Vaginal Ring
This prospective, randomized, single-blinded, placebo controlled trial will examine the safety and pharmacokinetics (PK) of a polyurethane tenofovir disoproxil fumarate (TDF) vaginal ring when used continuously for 14 consecutive…
- Trial name
- TDF IVR-001 (NCT02006264)
- Testing
- TDF Intravaginal Ring
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Albert Einstein College of Medicine
HIV, Alcoholism
Will Having Alcohol Treatment Improve Functioning?
The purpose of the study is to find out if a medication,naltrexone is helpful for HIV-infected women who sometimes drink too much.
- Trial name
- WHAT-IF (NCT01245647)
- Testing
- Naltrexone, 50mg, once per day for 4 months, Sugar pill, 50mg, once per day for 4 months
- Where
- 3 sites in United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- University of Florida
HIV Positive, Ageing
The Effects of Ageing on the 'Pharmacokinetic and Clinical Observations in People Over Fifty'
The purpose of this study is to identify medical conditions that may cause particular problems to individuals receiving care for HIV infection over the age of 50.
- Trial name
- POPPY (NCT01737047)
- Where
- 8 sites in Ireland, United Kingdom
- Volunteers
- 1,377 people, healthy volunteers welcome
- Sponsor
- Imperial College London
HIV Infections, Viral Load
Smart Linkage-to-HIV Care Via a Smartphone App
This randomized controlled trial evaluates the provision of individual patient laboratory results to newly diagnosed HIV positive smartphone users through a secure application (app) as a method to get them linked to and retained…
- Conditions
- HIV Infections, Viral Load, Patient Compliance, Antiretroviral Therapy
- Trial name
- SmartLtC (NCT02756949)
- Testing
- Smartphone application, Smartphone
- Where
- South Africa
- Volunteers
- 353 people
- Sponsor
- World Bank
Chronic Hepatitis C, Human Immunodeficiency Virus
A Phase 3, Open-label Study to Investigate the Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2, 3 and 4 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Adults
This is an Open-label Phase 3 study in adults with chronic genotypes 1, 2, 3, and 4 HCV infection who are co-infected with HIV-1.
- Trial name
- NCT01783678
- Testing
- Sofosbuvir, RBV
- Where
- 24 sites in Australia, France and 4 more
- Volunteers
- 275 people
- Sponsor
- Gilead Sciences
HIV-1 Infection
Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed-dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DF
The purpose of this randomized, open-label, multicenter, active-controlled Phase 3b study is to evaluate the noninferiority of the emtricitabine/rilpivirine/tenofovir disoproxil fumarate (FTC/RPV/TDF) single-tablet regimen (STR…
- Trial name
- NCT01252940
- Testing
- FTC/RPV/TDF, PI, RTV
- Where
- 111 sites in United States, Austria and 8 more
- Volunteers
- 482 people
- Sponsor
- Gilead Sciences
HIV Infections
Comparing Raltegravir Genital Tract Distribution in HIV-infected Men and Women
The purpose of this research study is to determine how much raltegravir gets into the male and female genital tract.
- Trial name
- NCT00745368
- Testing
- Raltegravir
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- University of Rochester
Acceptability of Health Care, HIV Infections
Addressing Violence and HIV Care Among Transgender Women
This project seeks to adapt and pilot a trauma-informed combination intervention named 'Kickin' it with the Gurlz' that was designed with, for, and by transgender women of color to improve HIV care continuum outcomes.
- Trial name
- NCT04813484
- Testing
- Kickin it with the Gulz
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- University of Michigan
HIV Infections
Maraviroc Intensification and Peripheral Blood Monocyte HIV DNA Levels
High levels of HIV infection within blood monocyte/macrophages (a type of white cells in the bloodstream) increases risk of dementia in HIV-infected individuals.
- Trial name
- NCT00987948
- Testing
- maraviroc (Selzentry)
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Hawaii
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.